FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia

Autor: D Sorcini, A Stella, A Scialdone, S Sartori, A Marra, R Rossi, F De Falco, FM Adamo, E Dorillo, C Geraci, R Arcaleni, C Rompietti, A Esposito, L Moretti, MG Mameli, MP Martelli, B Falini, P Sportoletti

Publikováno v: eJHaem, Vol 4, Iss 4, Pp 1100-1104 (2023)

Abstract One‐third of newly diagnosed adult acute myeloid leukaemia (AML) carry FLT3 mutations, which frequently occur together with nucleophosmin (NPM1) mutations and are associated with worse prognosis. FLT3 inhibitors are widely used in clinics

Externí odkaz: https://doaj.org/article/4c38b29289274a7990c345b01979a9de

Arsenic trioxide and all-trans-retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells

Autor: Mp, Martelli, Gionfriddo I, Mezzasoma F, Francesca Milano, Pierangeli S, Mulas F, Pacini R, Tabarrini A, Pettirossi V, Rossi R, Vetro C, Brunetti L, Sportoletti P, Tiacci E, Di Raimondo F, Falini B

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5ce488f8b6d848436689f7cb37e2e39c
http://europepmc.org/abstract/med/25795919

The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs).

Autor: Pierangeli S; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy., Donnini S; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy., Ciaurro V; MD Anderson Cancer Center, University of Texas, TX 78712, USA., Milano F; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy., Cardinali V; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy.; Hematology Department, 'Santa Maria della Misericordia' Perugia Hospital, 06129 Perugia, Italy., Sciabolacci S; Hematology Department, 'Santa Maria della Misericordia' Perugia Hospital, 06129 Perugia, Italy., Cimino G; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy.; Hematology Department, 'Santa Maria della Misericordia' Perugia Hospital, 06129 Perugia, Italy., Gionfriddo I; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy., Ranieri R; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy., Cipriani S; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy., Padiglioni E; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy., Iacucci Ostini R; Hematology Department, 'Santa Maria della Misericordia' Perugia Hospital, 06129 Perugia, Italy., Zei T; Hematology Department, 'Santa Maria della Misericordia' Perugia Hospital, 06129 Perugia, Italy., Pierini A; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy.; Hematology Department, 'Santa Maria della Misericordia' Perugia Hospital, 06129 Perugia, Italy., Martelli MP; Hematology and Clinical Immunology Section, Department of Medicine and Surgery, Center for Hemato-Oncological Research (CREO), University of Perugia, 06123 Perugia, Italy.; Hematology Department, 'Santa Maria della Misericordia' Perugia Hospital, 06129 Perugia, Italy.

Publikováno v: Cancers [Cancers (Basel)] 2024 Jul 27; Vol. 16 (15). Date of Electronic Publication: 2024 Jul 27.

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.

Autor: Marchesini M; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy.; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Gherli A; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy., Simoncini E; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy., Tor LMD; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy., Montanaro A; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy., Thongon N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vento F; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy.; Department of Medical Science, University of Ferrara, Ferrara, Italy., Liverani C; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Cerretani E; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy.; Department of Medical Science, University of Ferrara, Ferrara, Italy., D'Antuono A; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy., Pagliaro L; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy.; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy., Zamponi R; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy., Spadazzi C; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Follini E; Hematology and BMT Unit, Azienda USL Piacenza, Piacenza, Italy., Cambò B; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy., Giaimo M; Department of Medicine and Surgery, University of Parma, Parma, Italy.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy.; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy., Falco A; Department of Medicine and Surgery, University of Parma, Parma, Italy., Sammarelli G; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy., Todaro G; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy., Bonomini S; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy., Adami V; High-Throughput Screening Core Facility, CIBIO, University of Trento, Trento, Italy., Piazza S; High-Throughput Screening Core Facility, CIBIO, University of Trento, Trento, Italy.; Computational Biology group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy., Corbo C; University of Milano-Bicocca, Department of Medicine and Surgery, NANOMIB Center, Monza, Italy.; IRCCS Istituto Ortopedico Galeazzi, Milan, Italy., Lorusso B; Department of Medicine and Surgery, University of Parma, Parma, Italy., Mezzasoma F; Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria Della Misericordia Hospital, Perugia, Italy., Lagrasta CAM; Department of Medicine and Surgery, University of Parma, Parma, Italy., Martelli MP; Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria Della Misericordia Hospital, Perugia, Italy., La Starza R; Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria Della Misericordia Hospital, Perugia, Italy., Cuneo A; Department of Medical Science, University of Ferrara, Ferrara, Italy.; Hematology Unit, Azienda Ospedaliera-Universitaria S.ANNA, University of Ferrara, Ferrara, Italy., Aversa F, Mecucci C; Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria Della Misericordia Hospital, Perugia, Italy., Quaini F; Department of Medicine and Surgery, University of Parma, Parma, Italy., Colla S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roti G; Department of Medicine and Surgery, University of Parma, Parma, Italy. giovanni.roti@unipr.it.; Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy. giovanni.roti@unipr.it.; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. giovanni.roti@unipr.it.

Publikováno v: Nature communications [Nat Commun] 2024 Jun 04; Vol. 15 (1), pp. 4739. Date of Electronic Publication: 2024 Jun 04.

Real-world treatments and clinical outcomes in unfit AML patients receiving first-line treatment or best supportive care in Italy (CURRENT study).

Autor: Martelli MP; Hematology and Clinical Immunology, Department of Medicine and Surgery, University of Perugia, Italy., Di Renzo N; Hematology e Transplant Unit- Hematology/Oncology Department, 'Vito Fazzi' Hospital, Lecce, Italy., Curti A; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seragnoli', Bologna, Italy., Fracchiolla NS; UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy., Maurillo L; Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma 'Tor Vergata', Rome, Italy., Caira M; AbbVie srl, Campoverde di Aprilia, Latina, Italy., Finsinger P; AbbVie srl, Campoverde di Aprilia, Latina, Italy., Gualberti G; AbbVie srl, Campoverde di Aprilia, Latina, Italy., Ferrara F; Divisione di Ematologia, Ospedale Antonio Cardarelli, Napoli, Italy., Olivieri A; Hematology Department & Stem Cell Transplant Unit, Università Politecnica delle Marche, Ancona, Italy.

Publikováno v: Leukemia research reports [Leuk Res Rep] 2024 Feb 23; Vol. 21, pp. 100453. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).